BioSpace News Archive

The Barbara Ann Karmanos Cancer Institute welcomes Arnold D’Ambrosio as the new Chief Development Officer, effective Monday, July 10, 2023.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its participation at the 2023 US Hereditary Angioedema Association (HAEA) National Summit, which will include the presentation of three abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE). The US HAEA National Summit is being held in Orlando, Fla., from July 20-23, 2023.

C4 Therapeutics, Inc. announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 351,000 shares of the Company’s common stock to two new employees, with grants made on July 10 and July 17, 2023.

Virios Therapeutics, Inc. today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID.

Acumen Pharmaceuticals, Inc. will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD.

BioVie Inc. announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements.

Pardes Biosciences, Inc. announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing.

BioLineRx Ltd. today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase.

Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), and a leading ag-biologicals company that develops microbiome-based, computational driven bio-stimulant and bio-pesticide novel products, announced today a licensing agreement with Corteva Inc. (NYSE: CTVA), a leading ag innovation company.

Rhythm Pharmaceuticals, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 1, 2023 to report its second quarter 2023 financial results and provide a corporate update.